Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BIOCRATES Test Kit Helps Develop First Metabolomics-Based Blood Test for Alzheimer’s

Published: Tuesday, March 18, 2014
Last Updated: Thursday, March 20, 2014
Bookmark and Share
The test is capable of predicting, with 90% accuracy, the risk of Alzheimer’s disease 2–3 years before it has actually become clinically manifest.

The findings, published in Nature Medicine, were generated using the validated AbsoluteIDQ® p180 test kit by Austrian BIOCRATES Life Sciences AG, a leading developer of innovative metabolomics solutions.

A team of researchers in Georgetown, Washington DC, and Rochester, New York, has developed the world’s first blood test capable of predicting Alzheimer’s disease. The first-of-its-kind study, recently published in Nature Medicine, used the AbsoluteIDQ® p180 test kit by BIOCRATES Life Sciences AG, a leading Austrian biotech company specialized in targeted metabolite quantification. 

Alzheimer’s disease currently affects more than 35 million individuals worldwide, and this figure is expected to increase to up to 150 million by 2050. A cure for Alzheimer’s disease is currently not available, but early detection could contribute to substantially improving the situation of affected individuals. While biomarkers have long been expected to provide important clues to the early causes of Alzheimer’s disease, current biomarkers are either invasive, time-consuming, or costly. The team around Mapstone and Federoff now discovered that a set of 10 lipids from peripheral blood predicts the development of mild cognitive impairment or Alzheimer’s disease with over 90% accuracy and 2–3 years in advance. Although it will take some time to develop test versions fit for use in doctors’ offices, the findings by Mapstone et al. are an impressive example of the power of metabolomics in diagnosis and biomarker discovery.

AbsoluteIDQ p180 provides extensive metabolic information from a single targeted assay, quantifying 186 analytes from 5 substance classes in a high-throughput manner. It features the advanced proprietary MetIDQ™ software solution, requires minute sample volumes (10 µL), and is suitable for use with a wide range of biological samples, making it an excellent choice for researchers looking for a cost-effective solution to measure endogenous metabolites under quality-controlled conditions. The AbsoluteIDQ kits by BIOCRATES have been successfully applied in many different areas, including diabetes, nephrology, sepsis, and CNS disorders, in both clinical and pharmaceutical research.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BIOCRATES Goes Spain and Turkey
Austrian diagnostic expert in personalized medicine continues to expand its European distribution network.
Thursday, May 10, 2012
BIOCRATES and Selexis Join Forces to Optimize High-yield Mammalian Cell Cultures
The agreement enables both the parties to combine their knowledge to help lower overall manufacturing costs for pharmacologically active proteins.
Tuesday, August 31, 2010
BIOCRATES Joins European Research Consortium – SysKid
The Company has joined a multi-partner European research program dedicated to improving the diagnosis and treatment of chronic kidney disease.
Thursday, April 01, 2010
BIOCRATES’ Metabolomics Expertise Provides New Insight into Functional Genomics
German researchers used Biocrates’ metabolomics expertise in research linking the genetic make-up of an individual to differences in their metabolism.
Tuesday, February 03, 2009
BIOCRATES Participates in 2.9€ Million EU Cancer Diagnostics Project
The latest framework six EU projects called COBRED will use technology platforms to find diagnostic biomarkers for two of the most common cancers, Colon and Breast Cancer.
Friday, May 11, 2007
Biocrates Raises €5 Million in Venture Financing
This investment further strengthens Biocrates’ position in the field of high content analysis and discovery of multiparametric biomarkers.
Thursday, June 29, 2006
Scientific News
How Different People Respond To Aspirin
Study findings could be used to help identify those who would benefit most from aspirin use.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
A Metabolic Twist that Drives Cancer Survival
A novel metabolic pathway that helps cancer cells thrive in conditions that are lethal to normal cells has been identified.
Liver-On-Chip Tracks Dynamics of Cellular Function
Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
Living Off the Fat of the Land
Do cancer cells synthesize the parts for new cells or scavenge them from the environment?
Liver Disease, Obesity Linked
Kanazawa University researchers find similarities in the impeded signalling between central insulin activity and glucose production in the liver for both obese mice and mice that have had the vagus nerve removed.
Decoding Ties Between Vascular Disease, Alzheimer’s
NIH consortium uses big data, team science to uncover complex interplay of factors.
Gene Identified that May Worsen Cancer Outcome
Some patients with breast cancer, lung cancer and leukaemia seem to fare poorly after treatment because of the effects of a particular gene, a new study finds.
‘Big Data’ Drills Down Into Metabolic Details
Rice University bioengineers introduce efficient way to analyze, compare tissue-specific pathways.
New Approach to Curbing Cancer Cell Growth
Using a new approach, scientists at The Scripps Research Institute (TSRI) and collaborating institutions have discovered a novel drug candidate that could be used to treat certain types of breast cancer, lung cancer and melanoma.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!